On the other hand, the anti-diabetic agents such as pioglitazone and possibly sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-such as peptide-1 receptor agonist (GLP1RA) might possibly have a beneficial effect on NAFLD [133]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.